… protein, we determined the membrane protein expression in human liver samples and in our
in vitro cell models. We then related the protein expression to … together with expression data …

… characteristics or target protein expression levels may differ between patients and healthy
subjects. The need to conduct studies in patient populations has an impact on the feasibility …

… drugs. This review will summarize in particular clinically observed drug-drug interactions …
[P-glycoprotein (P-gp), breast cancer resistance protein (BCRP)], to inhibition of hepatic uptake …

… In conclusion, our study has shown that quantification of drug transport protein expression
can advance our understanding of interindividual differences in hepatic uptake and DDIs. We …

… the degree of interaction in each individual. Until recently, drug interaction derived from …
Recently, some forms of vitamin E have been shown to activate CYP3A gene expression via …

… It was hypothesized that these drugs may be influenced by loss-of-function polymorphisms
(eg, Q141K) and drug-drug interactions, possibly risking patient safety and impacting …

… of CYP3A4 expression levels coupled with the broad substrate specificity of the CYP3A4
protein represent a basis for drug interactions in patients undergoing combination drug therapy. …

… topology and cross-tissue gene expression correlations. The scoring system was validated
by known PD DDIs and agreed with similarities in drug clinical side effects, which we further …

… , increases Pgp expression in cells. This is a clear demonstration of drug–drug interactions
due to induction of Pgp by a drug. An unexpected drug–drug interaction was observed in …

… drug transporter P-glycoprotein we hypothesized that modulation of P-… expression and
function by SJW may contribute to the development of potentially harmful drug–drug interactions. …